Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SYS6052 Herpes Zoster Vaccine in Adults ≥ 40 Years
NCT07892989Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Jul 2027
01
Overview
A Phase 2 trial of SYS6052 in herpes zoster (HZ), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SYS6052
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07892989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892989.